Business
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company's current lease in Bedford, Massachusetts ends in late 2026.
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts","length":180,"tagName":"p","attribs":{}},{"type":"text","content":"Lease is One of the Largest in Greater Boston Life Sciences Over the Past Year","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters when the Company's current lease in Bedford, Massachusetts ends in late 2026.","length":436,"tagName":"p"},{"type":"image","alt":"Anchor Line Partners, LLC and Northwood Investors, LLC announced that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, MA.","displaySize":"","headline":null,"caption":"Anchor Line Partners, LLC and Northwood Investors, LLC announced that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, MA.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/6cb55d82e7f363fb403ed919b6094654"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BpIqf0iWn6koBUZHJ3T_PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6cb55d82e7f363fb403ed919b6094654","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2870789/Anchor_Line_Partners_long_term_lease.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Stoke is dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen as a first-in-class potential disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe neurodevelopmental disease that is characterized by recurrent seizures as well as significant cognitive and behavioral impairments.","length":433,"tagN...